Construction and immunogenicity of replication-competent adenovirus 5 host range mutant recombinants expressing HIV-1 gp160 of SF162 and TV1 strains.
An HIV Env immunogen capable of eliciting broad immunity is critical for a successful vaccine. We constructed and characterized adenovirus 5 host range mutant (Ad5hr) recombinants encoding HIV(SF162) gp160 (subtype B) and HIV(TV1) gp160 (subtype C). Immunization of mice with one or both induced cellular immunity to subtype B and C peptides by ELISpot, and antibody responses with high binding titers to HIV Env of subtypes A, B, C, and E. Notably, Ad5hr-HIV(TV1) gp160 induced better cellular immunity than Ad5hr-HIV(SF162) gp160, either alone or following co-administration. Thus, the TV1 Env recombinant alone may be sufficient for eliciting immune responses against both subtype B and C envelopes. Further studies of Ad5hr-HIV(TV1) gp160 in rhesus macaques will evaluate the suitability of this insert for a future phase I clinical trial using a replication-competent Ad4 vector.
Hidajat
Rachmat
R
Section on Immune Biology of Retroviral Infection, Vaccine Branch, National Cancer Institute, Bethesda, MD 20892, USA.
Kuate
Seraphin
S
Venzon
David
D
Kalyanaraman
Vaniambadi
V
Kalisz
Irene
I
Treece
James
J
Lian
Ying
Y
Barnett
Susan W
SW
Robert-Guroff
Marjorie
M
D016915:AIDS Vaccines / Q000096:biosynthesis / Q000276:immunology*; D000256:Adenoviridae / Q000235:genetics / Q000276:immunology*; D000818:Animals; D000917:Antibody Formation; D000918:Antibody Specificity; D005260:Female; D015483:HIV Antibodies / Q000097:blood; D019302:HIV Envelope Protein gp160 / Q000276:immunology*; D015658:HIV Infections / Q000276:immunology* / Q000517:prevention & control*; D015497:HIV-1 / Q000276:immunology; D007111:Immunity, Cellular; D051379:Mice; D008807:Mice, Inbred BALB C
D016915:AIDS Vaccines; D015483:HIV Antibodies; D019302:HIV Envelope Protein gp160; C514797:gp160 protein, Human immunodeficiency virus 1
Virology. 2008 Dec 20;382(2):217-25
18947849
AIDS. 2003 Jan 24;17(2):157-66
12545074
Proc Natl Acad Sci U S A. 1984 Jun;81(12):3655-9
6587381
Proc Natl Acad Sci U S A. 1985 Feb;82(3):689-93
2983309
Virology. 2008 Mar 15;372(2):273-90
18061231
J Immunol. 2003 Apr 15;170(8):4281-9
12682263
Virology. 2006 Sep 1;352(2):438-49
16780913
Biotechniques. 1993 Nov;15(5):856-62
8267981
Virology. 2001 Jan 5;279(1):1-8
11145883
Expert Rev Vaccines. 2004 Aug;3(4 Suppl):S105-17
15285710
Virology. 2007 Mar 30;360(1):218-34
17097711
Cell. 1979 Aug;17(4):957-66
114304
Vaccine. 2003 Sep 8;21(25-26):4022-35
12922139
Virology. 2006 Sep 15;353(1):83-98
16814356
J Virol. 1988 Jun;62(6):2059-66
2835510
J Virol. 1998 Jan;72(1):225-35
9420219
J Virol. 2006 Jun;80(12):6177-81
16731957
J Virol. 1997 Nov;71(11):8531-41
9343211
Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7777-81
1502197
J Virol. 1996 Jun;70(6):3724-33
8648707
J Virol. 1988 May;62(5):1606-16
2833610
Nucleic Acids Res. 1985 Feb 11;13(3):841-57
3839074
J Immunol. 2005 Feb 15;174(4):2185-9
15699150
Proc Natl Acad Sci U S A. 1989 Nov;86(21):8575-9
2813413
J Gene Med. 2004 Feb;6 Suppl 1:S172-83
14978760
J Virol. 2005 Nov;79(21):13338-49
16227256
J Virol. 2007 May;81(10):5024-35
17329327
Virology. 2008 May 10;374(2):322-37
18252262
J Virol. 2004 Mar;78(5):2212-21
14963117
J Virol. 2003 Aug;77(16):8607-20
12885879
J Virol. 1990 Sep;64(9):4390-8
2384920
Virology. 2002 Jan 5;292(1):107-13
11878913
Nat Med. 1997 Jun;3(6):651-8
9176492
J Exp Med. 1997 Feb 17;185(4):621-8
9034141
Virology. 2006 Aug 1;351(2):291-302
16678874
Curr Biol. 1996 Mar 1;6(3):315-24
8805248
AIDS. 2001 Feb;15 Suppl 1:S10-1
11293384
J Virol. 2006 Sep;80(18):9217-25
16940533
Proc Natl Acad Sci U S A. 2008 May 27;105(21):7552-7
18490657
J Virol. 1999 Dec;73(12):10489-502
10559367
J Virol. 2007 Apr;81(7):3414-27
17229693
J Virol. 1990 Jun;64(6):2669-77
1692346
JAMA. 2008 Aug 6;300(5):520-9
18677024
Expert Opin Biol Ther. 2008 Sep;8(9):1347-63
18694354
Int Rev Immunol. 2004 Jan-Apr;23(1-2):75-111
14690856
J Virol. 2005 Aug;79(16):10200-9
16051813
J Immunol. 2009 Mar 15;182(6):3718-27
19265150
J Virol. 2009 Jan;83(2):791-801
18971271